• About
• Links
• Contact
• Sitemap
• 

Global Pharmaceutical Biotech Market 2010-2025

The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms. Significant R&D efforts and innovative new treatments will lead to further expansion of the pharma biotech market. Global Pharmaceutical Biotech Market 2010-2025 – explains why that market will expand, revealing where the most exciting developments will lie.

This report examines markets for the following therapy classes:

• Oncology
• Insulins
• Immunosuppressive agents
• Autoimmune agents
• rythropoietin products
• Immunostimulating agents
• Interferons
• Pure vaccines
• Blood coagulation factors
• Growth hormones.

Which therapy classes will lead the pharma biotech market in future? Where will the best commercial opportunities lie from 2010 onwards? What are the most-crucial drivers and restraints in this increasingly-important market? This report will provide you with the information that you need to understand current trends and future directions in the global biopharma sector, seeing how it will further bolster the global pharma industry and market. In particular, we discuss prospects for the following products:

• Enbrel
• Remicade
• Avastin
• Humira
• MabThera
• Herceptin
• Lantus
• Neulasta
• Glivec
• Epogen

Comprehensive analysis of the global biopharma market:

Global Pharmaceutical Biotech Market 2010-2025 critically examines that sector through a comprehensive review of information sources and original analysis. The report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 100 tables and figures included. The result is a comprehensive market- and industry-centred study, with detailed analyses to benefit your work.

Why you should buy Global Pharmaceutical Biotech Market 2010-2025?

In this report you will receive the following benefits in particular:

• You will assess the current market for pharma biotech products
• You will review the overall pharma biotech market, including a global sales forecast for 2010 to 2025
• You will receive sales forecasts for the ten leading biotech therapy classes from 2010 to 2025, with detailed discussions
• You will receive sales forecasts for the leading products in this market from 2010 to 2025, with detailed discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2010 to 2025, with informed discussion
• You will examine commercial drivers and restraints in depth, exploring their significance
• You will discover the most-exciting pipeline developments in the sector, across a range of therapy classes
• Market growth, novel technologies and expansion into new therapeutic areas

Table of Contents

1. Executive Summary

1.1 Global Biotech Market Review
1.2 Aims, Scope and Format of the Report

2. An Introduction to Biotechnology

• 2.1 What is Biotechnology?
  • 2.1.1 The Major Focus Areas of Healthcare Biotechnology to Date
  • 2.1.2 The Launch of Recombinant Insulin in 1982 - the First Commercial Biotech Drug
• 2.2 The Power of Biopharmaceuticals: Turning Medicine around Therapeutically and Commercially
• 2.3 Biotechnologies and their Applications in Pharmaceutical Medicine
  • 2.3.1 Bioprocessing Technology
  • 2.3.2 Monoclonal Antibodies
  • 2.3.3 Recombinant DNA Technology
  • 2.3.4 Cloning
    • 2.3.4.1 Molecular Cloning
    • 2.3.4.2 Cellular Cloning
    • 2.3.4.3 Animal Cloning
    • 2.3.4.4 Protein Engineering
• 2.4 The Future Biopharmaceutical Market
• 2.4.1 The Number of Biotech Patents Granted from 1990 Onwards
• 2.5 Proteomics Constitutes the Next Step after Genomics
• 2.6 The Human Genome Project (HGP) and its Influence on Biotechnology
  • 2.6.1 Overall Project Goals
  • 2.6.2 Applications and Future Developments of the HGP

3. The Global Pharmaceutical Biotech Market, 2010-2025

• 3.1 The Global Pharmaceutical Biotech Market in 2009
• 3.2 The Pharmaceutical Biotech Market Out-Performs the Overall Pharmaceutical Market
• 3.3 The Global Pharmaceutical Biotech Market Forecast, 2010-2025
• 3.4 The Leading Biotech Therapy Classes, 2010-2025
• 3.5 The Oncology Class will Have the Greatest Market Share, 2010 to 2025.
• 3.6 Blockbuster Biotech Drugs in 2009
• 3.7 Which Drugs Will Show the Greatest Increases in Market Share?

4. The Leading Biotech Therapy Classes, 2010-2025

• 4.1 The Top 10 Biotech Therapy Classes in 2009
• 4.2 The Oncology Class Currently Leads the Biotech Market
  • 4.2.1 Long-Term Prospects for the Oncology Class, 2015-2025
• 4.3 Will the Insulins Class Exhibit Strong Growth?
• 4.4 Immunosuppressive Agents, 2010-2025
• 4.5 The Autoimmune Agents Class Will Show Initial Growth - Will it Last?
• 4.6 Erythropoietin Products - How Will Reported Safety Affect Sales?
  • 4.6.1 Erythropoietin Products Forecast, 2010-2025
• 4.7 Immunostimulating Agents - Will These Show Increase in Growth?
• 4.8 The Interferons Class: Sales, 2010-2025
  • 4.8.1 Long-Term Forecast for the Interferons Class
• 4.9 Pure Vaccines: Sales, 2010-2025
  • 4.9.1 Will Pure Vaccines Sales Decline after 2015?
• 4.10 Blood Coagulation Factors - Will These Show Steady Growth?
• 4.11 Growth Hormones Forecast, 2010-2025
• 4.12 Chapter Summary: The Top 10 Biotech Therapy Classes, 2010-2025

5. The Leading Pharma Biotech Products, 2010-2025

• 5.1 The 10 Leading Biotech Drugs Accounted for 40% of the Global Pharma Biotech Market Sales in 2009
• 5.2 Enbrel (Etanercept)
  • 5.2.1 Enbrel Currently Leads the Global Biotech Market
  • 5.2.2 Enbrel Will Show an Initial Increase in Sales
  • 5.2.3 Study Eases Fears of TNF Blocker Cancer Risk
  • 5.2.4 New Enbrel Delivery System
  • 5.2.5 Enbrel Lifecycle Management
  • 5.2.6 Sales of Enbrel Will Eventually Decline
  • 5.2.7 Enbrel faces Competition from Several Other Biotech Drugs
  • 5.2.8 Competition from Biosimilar Enbrel
• 5.3 Remicade (Infliximab)
  • 5.3.1 Remicade Will Reach Peak Revenues in 2013
  • 5.3.2 Remicade Revenues Will Decline from 2013 Onwards
  • 5.3.3 Remicade's Major Competitors
• 5.4 Avastin (Bevacizumab)
  • 5.4.1 Avastin Will Show High Growth - But Will it Last?
  • 5.4.2 New Avastin Drug Delivery Method for Treatment of Brain Tumours
• 5.5 MabThera/ Rituxan (Rituximab)
  • 5.5.1 MabThera/Rituxan Market Forecast, 2010-2015
  • 5.5.2 Long-Term Prospects for MabThera/Rituxan, 2015-2025
  • 5.5.3 Competition for MabThera/Rituxan
  • 5.5.4 Biosimilar MabThera/Rituxan
• 5.6 Humira (adalimumab)
  • 5.6.1 Humira - 2009's Fastest Growing Biotech Drug
  • 5.6.2 Humira Market Forecast, 2010-2015
  • 5.6.3 Long-Term Prospects for Humira
• 5.7 Herceptin (Trastuzumab)
  • 5.7.1 Short Term Forecast for Herceptin
  • 5.7.2 Long Term Prospects for Herceptin
  • 5.7.3 Herceptin Main Competitors, 2010-2025
• 5.8 Lantus (Insulin Glargine)
  • 5.8.1 Lantus Will Show an Initial Increase in Sales
  • 5.8.2 Will Lantus Sales Continue to Increase?
• 5.9 Neulasta (Pegfilgrastim)
  • 5.9.1 Neulasta Sales Forecast, 2010-2025
• 5.10 Glivec (Imatinib)
  • 5.10.1 Glivec Sales Forecast, 2010-2025
• 5.11 Epogen, Procrit (Epoetin Alfa)
  • 5.11.1 Epogen Sales Forecast, 2010-2025
  • 5.11.2 Epogen Safety and Efficacy
  • 5.11.3 Competition for Epogen
• 5.12 Chapter Summary - The Top 10 Leading Biotech Products, 2010-2025

6. Leading Companies in the Pharma Biotech Market

• 6.1 The Top Ten Pharma Biotechnology Companies Globally
• 6.2 Amgen - The Leading Pharma Biotech Company
• 6.3 Other Leading Companies in the Biotech Market
• 6.4 Leading Pharma Companies - Biotech Mergers and Acquisitions
  • 6.4.1 Roche and Genentech
• 6.5 The Continuing Success of Multinational Biopharmaceutical Companies is Dependent upon Important Drivers and Restraints
• 6.6 Companies are Changing their Strategic Focus to Overcome Challenges in the Worldwide Market

7. Issues Affecting the Pharma Biotech Sector

• 7.1 SWOT Analysis of the Global Pharma Biotech Sector
• 7.2 Market Drivers
• 7.3 Market Restraints
• 7.4 The Biotech Market is Rapidly Expanding
• 7.5 The Benefits of Biotechnological Drugs
• 7.6 Access to Capital
• 7.7 R&D in Biopharma
• 7.8 Regulatory Issues
  • 7.8.1 Biopharmaceuticals and the FDA
  • 7.8.2 FDA Approval Times
  • 7.8.3 High Regulatory Hurdles and Elevated Costs of Developing Biologic Drugs will Play to Whose Advantage?
• 7.9 Biotech's Delivery Challenge
  • 7.9.1 New Delivery Technologies: Pharmacy or Medical Benefit?
• 7.10 Increasing Capacity for Biotech Manufacturing
  • 7.10.1 Manufacturing Capacity Shortfall?
• 7.11 The Costs of Biopharmaceuticals
• 7.12 Time Taken to Develop a Biotech Drug
• 7.13 Significant Future Biopharma Innovation will Result from Academia
• 7.14 The Risky Path from Bench to Market
• 7.15 Biogeneric Threats
  • 7.15.1 Bioequivalence Requirements Will Restrict the Rate and Volume of Market Entry for Biosimilar Drugs
  • 7.15.2 Healthcare Costs are Rising and Biotech Drugs form a Large Part of those Costs in Leading Nations
  • 7.15.3 Can the Next Generation of Biotech Drugs Restrain Growth of the Biosimilars Sector?
• 7.16 Dependence upon Venture Capital Investment
• 7.17 Challenges and Issues for the Future Biotech Industry

8. Global Pharma Biotech Market by Region

• 8.1 The World Pharma Biotech Market is Dominated by the US
• 8.2 The Japanese, Latin American and European Biotech World Market Shares are set to Increase by 2015
• 8.3 The US Biotech Market Will Retain its World Dominance

9. The Pharma Biotech R&D Pipeline

• 9.1 Technology Driving Biotech Pipeline
• 9.2 The Late-Stage Biotech Oncology Pipeline
• 9.3 The Late-Stage Human Insulin Pipeline
• 9.4 The Late-Stage Immunosuppressive Agents Pipeline
• 9.5 The Late-Stage Autoimmune Agents Pipeline
• 9.6 The Late-Stage Erythropoietin Products Pipeline
• 9.7 The Late-Stage Immunostimulating Agents Pipeline
• 9.8 The Late-Stage Interferons Pipeline
• 9.9 The Late-Stage Pipeline for Pure Vaccines
• 9.10 The Late-Stage Pipeline for Blood Coagulation Factors
• 9.11 The Late-Stage Pipeline for Growth Hormones
• 9.12 The Future of Biotech R&D

10. Venture Capital Investment in Healthcare Biotechnology

• 10.1 What is Venture Capital Investment?
• 10.2 What Do VC's Offer?
• 10.3 What Do Venture Capitalists Do?
• 10.4 Who are Venture Capitalists for Healthcare?
  • 10.4.1 Banks as Venture Capitalists
  • 10.4.2 Business Angels as Venture Capitalists
  • 10.4.3 Corporate or Direct Investors as Venture Capitalists
  • 10.4.4 Government Grants and Governments as Venture Capitalists
  • 10.4.5 Venture Capital Firms
  • 10.4.6 Other Types of Venture Capitalist
• 10.5 Why Do Many Biotech Companies Need VC Funding?

11. Biosimilar Drugs

• 11.1 The Emergence of Biosimilars (Follow-on Biologics)
  • 11.1.1 Patent Expiry for Key Biotech Drugs
  • 11.1.2 Terms are Important
• 11.2 Improved Technology Has Strengthened the Case for Biosimilars
• 11.3 Bioequivalence Will Remain Challenging
• 11.4 Biotech Drugs are Expensive to Produce
• 11.5 Regulators and Patients are Cautious over Safety
• 11.6 The Next Generation of Biotech Drugs Will Restrain Growth in Biosimilars
• 11.7 Regulations are the Main Concern for Biosimilars
  • 11.7.1 FDA Biogeneric/Biosimilar Approval Pathway?
• 11.8 The Key Question for Biosimilars

12. Conclusions

• 12.1 The Global Biotech Market: Summary
• 12.2 The Top 10 Biotech Products of 2009 Achieved Impressive Sales Results
• 12.3 Nine of the Current Top 10 Therapy Classes Will Show Growth in Future
• 12.4 Market Drivers
• 12.5 Market Restraints
• 12.6 Growth of the Biopharma Market Will Continue

List of Tables

• Table 2.1 Definitions of Selected Biopharmaceuticals
• Table 2.2 Summary of Biotechnologies, 2009
• Table 3.1 Global Pharmaceutical Biotech Sales Forecast ($bn), 2010-2016
• Table 3.2 Global Pharmaceutical Biotech Sales Forecast ($bn), 2017-2025
• Table 3.3 Leading Biotech Therapy Classes Sales Forecast ($bn), 2010-2016
• Table 3.4 Leading Biotech Therapy Classes Sales Forecast ($bn), 2017-2025
• Table 3.5 Market Shares (%) of the Leading Therapeutic Classes, 2009, 2015 and 2025
• Table 3.6 Leading Biotech Drugs Sales Forecast ($m), 2010-2016
• Table 3.7 Leading Biotech Drugs Sales Forecast ($m), 2017-2025
• Table 3.8 Market Shares (%) of the Top Ten Drugs, 2009, 2015 & 2025
• Table 4.1 Oncology Class Sales Forecast ($bn), 2010-2016
• Table 4.2 Oncology Class Sales Forecast ($bn), 2017-2025
• Table 4.3 Human Insulins Class Sales Forecast ($bn), 2010-2016
• Table 4.4 Human Insulins Class Sales Forecast ($bn), 2017-2025
• Table 4.5 Immunosuppressive Agents Class Sales Forecast ($bn), 2010-2016
• Table 4.6 Immunosuppressive Agents Class Sales Forecast ($bn), 2017-2025
• Table 4.7 Autoimmune Agents Class Sales Forecast ($bn), 2010-2016
• Table 4.8 Autoimmune Agents Class Sales Forecast ($bn), 2017-2025
• Table 4.9 Erythropoietin Products Class Sales Forecast ($bn), 2010-2016
• Table 4.10 Erythropoietin Products Class Sales Forecast ($bn), 2017-2025
• Table 4.11 Immunostimulating Agents Class Sales Forecast ($bn), 2010-2016
• Table 4.12 Immunostimulating Agents Class Sales Forecast ($bn), 2017-2025
• Table 4.13 Interferons Class Sales Forecast ($bn), 2010-2016
• Table 4.14 Interferons Class Sales Forecast ($bn), 2017-2025
• Table 4.15 Pure Vaccines Class Sales Forecast ($bn), 2010-2016
• Table 4.16 Pure Vaccines Class Sales Forecast ($bn), 2017-2025
• Table 4.17 Blood Coagulation Factors Class Sales Forecast ($bn), 2010-2016
• Table 4.18 Blood Coagulation Factors Class Sales Forecast ($bn), 2017-2025
• Table 4.19 Growth Hormones Class Sales Forecast ($bn), 2010-2016
• Table 4.20 Growth Hormones Class Sales Forecast ($bn), 2017-2025
• Table 4.21 Top 10 Classes, Rank Comparison, 2009, 2015 & 2025
• Table 5.1 Enbrel Sales Forecast ($m), 2009-2016
• Table 5.2 Enbrel Sales Forecast ($m), 2017-2025
• Table 5.3 Remicade Sales Forecast ($m), 2010-2016
• Table 5.4 Remicade Sales Forecast ($m), 2017-2025
• Table 5.5 Avastin Sales Forecast ($m), 2009-2016
• Table 5.6 Avastin Sales Forecast ($m), 20017-2025
• Table 5.7 MabThera/Rituxan Sales Forecast ($m), 2009-2016
• Table 5.8 MabThera/Rituxan Sales Forecast ($m), 2017-2025
• Table 5.9 Humira Sales Forecast ($m), 2009-2016
• Table 5.10 Humira Sales Forecast ($m), 2017-2025
• Table 5.11 Herceptin Sales Forecast ($m), 2009-2016
• Table 5.12 Herceptin Sales Forecast ($m), 2017-2025
• Table 5.13 Lantus Sales Forecast ($m), 2009-2016
• Table 5.14 Lantus Sales Forecast ($m), 2017-2025
• Table 5.15 Neulasta Sales Forecast ($m), 2009-2016
• Table 5.16 Neulasta Sales Forecast ($m), 2017-2025
• Table 5.17 Glivec Sales Forecast ($m), 2009-2016
• Table 5.18 Glivec Sales Forecast ($m), 2017-2024
• Table 5.19 Epogen Sales Forecast ($m), 2009-2016
• Table 5.20 Epogen Sales Forecast ($m), 2017-2025
• Table 5.21 Top 10 Products: Ranked Comparison, 2009, 2015 & 2025
• Table 6.1 The Top 10 Biotech Companies: Revenues ($m) and Market Shares (%), 2008
• Table 7.1 SWOT Analysis of the Global Pharma Biotech Market, 2010-2025
• Table 8.1 Global Market Shares (%) & Revenues ($m) by Region/Country, 2009
• Table 8.2 Pharma Biotech Sales Forecast ($m) by Country/Region, 2010-2016
• Table 8.3 Pharma Biotech Sales Forecast ($m) by Country/Region, 2017-2025
• Table 8.4 Market Shares (%) by Country/Region, 2009, 2015 & 2025
• Table 9.1 The Late-Stage Oncology Pipeline, 2009
• Table 9.2 The Late-Stage Human Insulins Pipeline, 2009
• Table 9.3 The Late-Stage Immunosuppressive Agents Pipeline, 2009
• Table 9.4 The Late-Stage Autoimmune Agents Pipeline, 2009
• Table 9.5 The Late-Stage Erythropoietin Products Pipeline, 2009
• Table 9.6 The Late-Stage Immunostimulating Agents Pipeline, 2009
• Table 9.7 The Late-Stage Interferons Pipeline, 2009
• Table 9.8 The Late-Stage Pipeline for Pure Vaccines, 2009
• Table 9.9 The Late-Stage Pipeline for Blood Coagulation Factors, 2009
• Table 9.10 The Late-Stage Pipeline for Growth Hormones, 2009

List of Figures

• Figure 3.1 Global Pharmaceutical Biotech Sales Forecast ($bn), 2010-2025
• Figure 3.2 Leading Biotech Therapy Classes (Sales in $m), 2010-2025
• Figure 3.3 Market Shares (%) of the Leading Therapy Classes, 2009
• Figure 3.4 Market Shares (%) of the Leading Therapy Classes, 2015
• Figure 3.5 Market Shares (%) of the Leading Therapy Classes, 2025
• Figure 3.6 Top 10 Biotech Drugs Market Shares (%), 2009
• Figure 3.7 Top 10 Biotech Drugs Market Shares (%), 2015
• Figure 3.8 Top Ten Biotech Drugs Market Shares (%), 2025
• Figure 4.1 Oncology Class Sales Forecast ($bn), 2010-2025
• Figure 4.2 Human Insulins Class Sales Forecast ($bn), 2010-2025
• Figure 4.3 Immunosuppressive Agents Class Sales Forecast ($bn), 2010-2025
• Figure 4.4 Autoimmune Agents Class Sales Forecast ($bn), 2010-2025
• Figure 4.5 Erythropoietin Products Class Sales Forecast ($bn), 2010-2025
• Figure 4.6 Immunostimulating Agents Class Sales Forecast ($bn), 2010-2025
• Figure 4.7 Interferons Class Sales Forecast ($bn), 2010-2025
• Figure 4.8 Pure Vaccines Class Sales Forecast ($bn), 2010-2025
• Figure 4.9 Blood Coagulation Factors Class Sales Forecast ($bn), 2010-2025
• Figure 4.10 Growth Hormones Class Sales Forecast ($bn), 2010-2025
• Figure 4.11 Top Ten Therapy Classes Sales ($bn), 2009, 2015 & 2025
• Figure 5.1 Enbrel Sales Forecast ($m), 2010-2025
• Figure 5.2 Remicade Sales Forecast ($m), 2010-2025
• Figure 5.3 Avastin Sales Forecast ($m), 2010-2025
• Figure 5.4 MabThera/Rituxan Sales Forecast ($m), 2010-2025
• Figure 5.5 Humira Sales Forecast ($m), 2010-2025
• Figure 5.6 Herceptin Sales Forecast ($m), 2010-2025
• Figure 5.7 Lantus Sales Forecast ($m), 2010-2025
• Figure 5.8 Neulasta Sales Forecast ($m), 2010-2025
• Figure 5.9 Glivec Sales Forecast ($m), 2010-2025
• Figure 5.10 Epogen Sales Forecast ($m), 2010-2025
• Figure 5.11 Top Ten Biotech Drugs Sales ($m), 2009, 2015 & 2025
• Figure 6.1 The Top Ten Biotech Companies, Revenues ($m), 2008
• Figure 6.2 The Top Ten Biotech Companies, Market Shares (%), 2008
• Figure 8.1 Pharma Biotech Market Shares (%) by Country/Region, 2009
• Figure 8.2 Pharma Biotech Market Shares (%) by Country/Region, 2015
• Figure 8.3 Pharma Biotech Market Shares (%) by Country/Region, 2025

Other users found this report page using the following search terms: biotech biologic Enbrel Remicade Avastin Humira MabThera Herceptin Lantus Neulasta Glivec Epogen market 2010 global biotech sales pharmaceutical biotechnology forecast 2009 pharma

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.